Join us at 10am BST / 9am GMT on the 18th May for the first episode in our two-part series on 'Peptide Therapeutics: Disease screening and Drug Design'. Sign up here to receive email updates about the series. In this collection of expert-led sessions, we will learn about advancements in peptide-based drugs - medicines which have become a promising alternative to antibiotics, showing to be safer to use and cheaper to make. Click here to follow this Researcher profile for upcoming series on this topic (Hint: there will be another one coming up in the autumn!)
This first episode will feature Dr Miguel Fernández de Ullivarri, from the APC Microbiome Institute. 
Episode summary:

The development of new multi-resistant strains, the side-effects caused by current antifungal drugs and the high morbidity of Vulvovaginal Candidiasis (VVC) and its recurrent form (RVVC) indicates that it is important to develop new therapeutic tools for the treatment of these diseases.

To treat these diseases both safely and effectively, we are developing new antifungal molecules based on the so-called Killer Peptide. We are also developing a new technology that allow us to easily increase the potency of other antimicrobial peptides. In this way, a second generation of peptide-based antimicrobials with enhanced potency is currently being developed.

This arsenal of new molecules are potentially suitable for the production and marketing of novel therapeutics that would be able to treat VVC and RVVC in an effective and safe manner.


To speak at a Researcher Live session, please email kristine.lennie@researcher-app.com 


Series programme:


  • 18th May, 10am BST - Dr Miguel Fernández de Ullivarri, Postdoctoral Research Fellow at APC Microbiome Institute:  ‘A Killer solution for vaginal candidiasis: New generation of antifungal peptides


  • 23rd June, 10am BSTDr Garry Laverty , Senior Lecturer at Queen’s University in Belfast:  ‘Peptide Hydrogel and Nanotubes for Drug Delivery and Biomaterial Applications’
Date and Time
Wednesday, May 18, 2022 10:00 am BST / 09:00 am GMT
Speakers Avatar Dr Miguel Fernández de Ullivarri, Postdoctoral Research Fellow at APC Microbiome Institute

Dr. Miguel Fernandez de Ullivarri (34) was born in Argentina. After graduating as BSc in Biotechnology in 2010, he obtained his PhD in Biochemistry at Universidad Nacional de Tucuman in 2015, studying the antimicrobial killer toxins produced by native wine yeasts from Northwestern Argentina. He carried out his first Postdoctoral research at INSIBIO, Argentina, on the recombinant expression antigens from the parasite Leishmania braziliensis for the development of novel vaccines for Leishmaniasis. In 2018, he moved to Cork, Ireland as a Marie Curie Fellow to work at APC Microbiome in University College Cork with Prof. Paul Cotter, where he started his current project on novel antifungal peptides for the treatment of vaginal candidiasis. Dr. Fernandez de Ullivarri is still working on this and other applied science projects on antimicrobials, such as the enhancement of Nisin A production by genetic engineering of Lactococcus lactis with the company ImmuCell (USA).

DOI: nusAKZCcX8owF3CeAMH5_prepost_1

You might also like
Discover & Discuss Important Research

Keeping up-to-date with research can feel impossible, with papers being published faster than you'll ever be able to read them. That's where Researcher comes in: we're simplifying discovery and making important discussions happen. With over 19,000 sources, including peer-reviewed journals, preprints, blogs, universities, podcasts and Live events across 10 research areas, you'll never miss what's important to you. It's like social media, but better. Oh, and we should mention - it's free.

  • Download from Google Play
  • Download from App Store
  • Download from AppInChina

Researcher displays publicly available abstracts and doesn’t host any full article content. If the content is open access, we will direct clicks from the abstracts to the publisher website and display the PDF copy on our platform. Clicks to view the full text will be directed to the publisher website, where only users with subscriptions or access through their institution are able to view the full article.